Literature DB >> 19591893

A case-control association study between the CYP3A4 and CYP3A5 genes and schizophrenia in the Chinese Han population.

Jing Du1, Yifeng Xu, Shiwei Duan, Aiping Zhang, Jiekun Xuan, Lei Wang, Lan Yu, Hongsheng Wang, Xingwang Li, Guoyin Feng, Lin He, Qinghe Xing.   

Abstract

In this study, variants of two genes coding for cytochrome P450 enzyme (CYP3A4 and CYP3A5) were analysed in a case-control sample using 398 schizophrenic patients and 391 healthy controls. All subjects were unrelated Han Chinese from Shanghai. No difference was observed on the allelic or genotypic distribution of CYP3A4 and CYP3A5 gene polymorphisms between the groups. However, the two-marker haplotypes covering components CYP3A41G and CYP3A53 were observed to be significantly associated with schizophrenia (corrected global p=0.0009). In addition, we identified one common risk haplotype, G/G (present in 59.5% of the general population). The results suggest that CYP3A4 and CYP3A5 might play a role in genetic susceptibility to schizophrenia. However, confirmatory studies in independent samples are needed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19591893     DOI: 10.1016/j.pnpbp.2009.06.023

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  2 in total

Review 1.  Pharmacogenomics can improve antipsychotic treatment in schizophrenia.

Authors:  Qingqing Xu; Xi Wu; Yuyu Xiong; Qinghe Xing; Lin He; Shengying Qin
Journal:  Front Med       Date:  2013-04-21       Impact factor: 4.592

2.  Evaluation of genetic polymorphism of CYP3A5 in normal healthy participants from western India - A cross-sectional study.

Authors:  Miteshkumar Rajaram Maurya; Sunanda Gautam; Jeffrey Pradeep Raj; Shruti Saha; Sanchita Ambre; Aishwarya Thakurdesai; Aditya Shah; Urmila Mukund Thatte
Journal:  Indian J Pharmacol       Date:  2022 Mar-Apr       Impact factor: 2.833

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.